Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.
Feature|Articles|September 30, 2025
- Vol.26/No.11
- Volume 26
- Issue 11
Real-World Evidence Complements and Contextualizes Randomized Clinical Trial Insights in Colorectal Cancer
Author(s)Ashley Chan
Fact checked by: Chris Ryan
Although clinical trials are considered a “gold standard” in identifying the efficacy of treatments, real-world data help address unmet needs in colorectal cancer.
Advertisement
Advertisement
As data from prospective clinical trials continue to drive change and bring newer treatments to the colorectal cancer (CRC) realm, real-world evidence has helped further address unmet needs for patients who may be ineligible for clinical trials or descend from underrepresented populations.
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
PDS Biotechnology will prioritize the IL-12 immunocytokine PDS0301 in metastatic colorectal cancer and pursue a partnership strategy for PDS0101.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
An FDA advisory committee will meet in September to review the premarket approval application for the Galleri multi-cancer early detection blood test.
Advertisement
Advertisement